Sensitivity of Lateral Flow technique for Evaluation of Inactivated Rift Valley Fever Virus Vaccine in Comparison with Serum Neutralization Test

Rift Valley fever virus.

Vet Med Today: Zoonosis Update 883 R Valley fever virus is a mosquito-borne pathogen of livestock and humans that historically has been responsible for widespread and devastating outbreaks of severe disease throughout Africa and, more recently, the Arabian Peninsula. The virus was first isolated and RVF disease was initially characterized following the sudden deaths (over a 4-week period) of ap...

Comparison of Micro Neutralization Test with Hemadsorption-Inhibition Test, and Immunoflrorescence Technique for Detecting Mumps Antibodies

A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep

Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease outbreaks in Africa and the Arabian Peninsula. The virus has great potential for transboundary spread due to the presence of competent vectors in non-endemic areas. There is currently no fully licensed vaccine suitable for use in livestock or humans outside endemic areas. Here we report the evaluation of the ef...

Mosquito Species for Rift Valley Fever Virus

Ahstract. Selected North American mosquito species were evaluated as potential vectors I of Rift Valley fever virus. Field Populations of .1edes canadensis Ae. camawr, A(. everu' tans. .,ie. so[iitans, .e. tae'tlorh Iteh,. .ic. trseratus. .1 ntophwk' hradleti-crucians, ( u/c. alinariis. (vtursais. and (V. erritanS perorally exposed to 10"'-10-plaque forming units of Rift ValLv fever virus rcd.J...

Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.

An investigational, formalin-inactivated Rift Valley fever (RVF) vaccine, known as The Salk Institute-Government Services Division (TSI-GSD) 200 vaccine, was administered to 1860 at-risk subjects (5954 doses) between 1986 and 2004 as a three-dose primary series (days 0, 7, and 28) followed by booster doses as needed for declining titers. An initial positive serological response (PRNT(80)≥1:40) ...